Prostate-specific membrane antigen-based imaging in prostate cancer: Impact on clinical decision making process

Prostate

Volumn 75, Issue 7, 2015, Pages 748-757

  Demirkol, Mehmet Onur ^a,b   Acar, Ömer ^a   Uçar, Burcu ^b   Ramazanoʇlu, Sultan Rana ^b   Saʇlican, Yeşim ^c   Esen, Tarik D L D A L ^a,b  

^a KOÇ UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

Author keywords

cancer; ligand; nuclear imaging; prostate

Indexed keywords

GALLIUM 68; LUTETIUM 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; YTTRIUM 90; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; MEMBRANE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; MALE; METASTASIS; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SYSTEMIC THERAPY; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; METABOLISM; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84926526856     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22956     Document Type: Article

References (30)

1. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D, Soerjomataram I,. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2013;Oct 8. pii: S0959-8049(13) 00842-00843. doi: 10.1016/j.ejca.2013.09.002. [Epub ahead of print].
2. Horoszewicz JS, Kawinski E, Murphy,. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-935.
3. Israeli RS, Powell CT, Fair WR, Heston,. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227-230.
4. Israeli RS, Powell CT, Corr JG, Fair WR, Heston,. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-1811.
5. Troyer JK, Beckett ML, Wright GL Jr,. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62: 552-558.
6. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer,. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate 2000; 43: 150-157.
7. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy,. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82: 2256-2261.
8. Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C, Kijima,. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int 2008; 58: 687-694.
9. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172.
10. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong,. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009; 69: 1101-1108.
11. Wright GL, Jr, Haley C, Beckett ML, Schellhammer PF,. Expression of prostate-specifc membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995; 1: 18-28.
12. Wright GL, Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R,. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
13. Sweat SD, Pacelli A, Murphy A, Bostwick,. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-640.
14. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa,. Prostate specific membrane antigen-based imaging. Urol Oncol 2013; 31: 144-154.
15. Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka,. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga] Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (Basel) 2014; 7: 779-796.
16. Sweat SD, Pacelli A, Murphy GP, Bostwick,. Prostate-specific membrane antigen expression is greatest in prostate adenocarcino-ma and lymph node metastases. Urology 1998; 52: 637-640.
17. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172.
18. Schumacher J, Maier-Borst,. A new 68Ge/Ga-68 radioisotope generator system for production of Ga-68 in dilute HCl. Int J Appl Radiat Isot 1981; 32: 31-36.
19. Ghosh A, Heston,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Bio-chem 2004; 91: 528-539.
20. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich,. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69: 6932-6940.
21. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23: 688-697.
22. Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper,. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51: 4504-4517.
23. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper,. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012; 53: 1883-1891.
24. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut C, Zechmann,. [(68)Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with (18)F-FECH. Eur J Nucl Med Mol Imaging 2012; 39: 1085-1086.
25. Hovels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz,. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis. Clin Radiol 2008; 63: 387-395.
26. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn,. Eur J Nucl Med Mol Imaging 2014; 41: 11-20.
27. Stone NN, Unger P, Crawford ED, Stock RG,. Diagnosis and management of local recurrence after low-dose-rate brachytherapy. Brachytherapy 2014;pii: S1538-4721(14) 00638-00632.
28. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwill C, Haufe S, Haberkorn U, Zechmann,. Eur J Nucl Med Mol Imaging 2013; 40: 486-495.
29. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes,. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172.
30. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy,. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82: 2256-2261.